## Extended table of contents

<table>
<thead>
<tr>
<th>Acknowledgements</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword by the Directors-General</td>
<td>6</td>
</tr>
<tr>
<td>An integrated health, trade and IP approach to respond to the COVID-19 pandemic</td>
<td>7</td>
</tr>
<tr>
<td>Executive Summary</td>
<td>16</td>
</tr>
</tbody>
</table>

### I. Medical technologies: the fundamentals 24

#### A. Public health and medical technologies: the imperative for international cooperation 26

1. Policy coherence 26
2. Scope of the study 27
3. The need for this study 27
4. Who should read this study? 28

#### B. The cooperating agencies: the WHO, WIPO and the WTO 29

1. World Health Organization 29
2. World Intellectual Property Organization 30
3. World Trade Organization 31
4. Trilateral cooperation 31
5. Other international key stakeholders 32

#### C. The global burden of disease and global health risks 33

1. Current estimates of global and regional burden of disease 33
2. Trends: major cause groups contributing to the total disease burden 33
3. Trends in global health risks 35

#### D. Factors shaping public health policy 36

1. Seeking effective outcomes within a complex policy environment 36
2. Transforming policy intersections 36
3. Building stronger links between local, national and global levels 37
4. The empirical challenge: an accessible base for policy 39

### II. The policy context for action on innovation and access 42

#### A. Public health policy 44

1. Health and human rights 44
2. Access to essential medicines: an indicator for the fulfilment of the right to health 46
3. Universal access and the UN Sustainable Development Goals 46
4. Public health, innovation and access in the WHO 48
   (a) Resolutions dealing with public health, intellectual property and trade 48
   (b) The Commission on Intellectual Property Rights, Innovation and Public Health 49
   (c) The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property 49
   (d) Other developments in the WHO 50
5. Cross-cutting efforts to tackle antimicrobial resistance 51

6. Regulation of health technologies 52
   (a) Why regulate medical products? 53
   (b) Clinical trials 54
   (c) Research ethics 54
      (i) Clinical trial ethics 54
      (ii) Health databases and biobanks 55
      (iii) Bioethics 55
   (d) Biotherapeutic products 56
      (i) Background 56
      (ii) Pathways for the registration of biotherapeutic products 56
      (iii) What will be the effect of SBPs on prices? 57
   (e) Future of regulation 57
   (f) Regulatory exclusivities 59
   (g) Patent linkage 61

B. Intellectual property, trade and other policy dimensions 63

1. Intellectual property systems 63
   (a) Introduction to IP systems 63
   (b) Patent law and policy 66
      (i) The rationale of the patent system 66
      (ii) The international framework 66
      (iii) Basic patent issues 68
      (iv) Patent procedures 71
      (v) Review procedures 72
      (vi) Rights conferred by a patent 72
      (vii) Exceptions and limitations to patent rights 73
      (viii) Patent information 74
      (ix) Patent status and legal status information 76
      (x) Patent landscapes and medical technologies 78
      (xi) Filing trends under the Patent Cooperation Treaty system 78
   (c) Protection of test data 80
      (i) How test data are protected 80
      (ii) Innovation and access dimensions 82
      (iii) Distinction between the protection of patents and of test data 82
      (iv) Open access to test data 83
   (d) Trademarks 83
      (i) The trademark system 83
      (ii) Trademarks and international non-proprietary names (INNs) for active pharmaceutical ingredients 85
      (iii) Trademarks and unfair competition 86
(iv) Regulatory approval of proprietary names 86
(v) Trademark cluttering 86
(vi) Non-traditional marks 86
(vii) Standardized packaging 87
(e) Copyright 87
   (i) Copyright and pharmaceutical package inserts 87
   (ii) Exceptions and limitations – text and data mining 88
   (iii) Licensing schemes 88
   (iv) Orphan works access licensing schemes 88
   (v) Software licensing and eHealth 88
(f) Enforcement 89
   (i) The link between intellectual property right enforcement and public health 90
   (ii) Enforcement provisions of the TRIPS Agreement 90
   (iii) The WIPO Advisory Committee on Enforcement 90
(g) Flexibilities under the TRIPS Agreement and the Doha Declaration 90
   (i) Flexibilities in the IP system 90
   (ii) Background to the Doha Declaration 91
   (iii) Content of the Doha Declaration 93
   (iv) Implementation of the Doha Declaration 93
   (v) Least-developed country transition periods 94
(h) Terms of accession to the WTO 94
2. Competition law and policy 95
   (a) The dual function of competition law and policy 95
   (b) The interface between competition law and policy, and IP protection 96
      (i) Addressing competition policy concerns in the legal framework for IP protection 96
      (ii) Enforcing competition law in the IP context 97
   (c) Preserving innovation: merger control in the pharmaceutical sector 97
   (d) Unfair competition 98
3. Trade policy settings 98
   (a) Tariffs 98
   (b) Non-tariff measures 99
      (i) Sanitary and phytosanitary measures 99
      (ii) Technical barriers to trade 99
   (c) Trade in services 100
      (i) The multilateral legal framework 101
      (ii) The scope of GATS commitments in health-related sectors 101
      (iii) The growing economic importance of trade in health services and the impact of GATS commitments 102
      (iv) Challenges linked to the opening of trade in health services 102
4. Government procurement
   (a) The importance of a transparent and competitive procurement process for
       the health sector
   (b) Procurement of medical technologies and health services under the GPA
       (i) GPA coverage
       (ii) The magnitude of GPA parties’ health-related procurement
5. Free trade agreements
   (a) Trends in trade negotiations beyond the multilateral arena
   (b) The non-discrimination principles and FTAs
   (c) Intellectual property standards
   (d) Investor–state dispute settlement
   (e) Commitments in other areas
6. Resolving trade disputes at the WTO
C. Economics of innovation and access to medical technologies
D. Genetic resources, traditional knowledge and traditional medicine
   1. Traditional medicine knowledge systems
   2. Traditional medical knowledge in health and IP policy
   3. Traditional medicines regulation
   4. Concerns about misappropriation of traditional knowledge and genetic resources
   5. New approaches to IP protection of traditional medical knowledge
      (a) Why protect traditional knowledge?
      (b) What is to be protected, and for whose benefit?
      (c) What is it to be protected from?
      (d) How can traditional knowledge be protected?
      (e) Documentation
III. Medical technologies: the innovation dimension
A. Historical pattern of medical R&D
   1. Innovation for medical technologies in context
   2. From early discoveries to “wonder drugs”
   3. Growth and evolution of the pharmaceutical industry
   4. From non-exclusive licensing to restricted production
   5. Trends in R&D
B. The current R&D landscape
   1. A time of challenges and opportunities for pharmaceutical R&D
   2. The key role of public-sector research in medical R&D
   3. Medical R&D costs
   4. Incentive models in the innovation cycle
      (a) The innovation cycle
      (b) Absence of self-sustaining innovation cycle in the case of small markets,
          low incomes or low sales volumes
### Building innovation networks

**Overview of innovation structures**

- **Vaccines: a distinct challenge for innovation**
  - New vaccine innovation in the 21st century
  - The role of developing-country manufacturers

### Challenges in cancer medicines R&D

### Orphan drugs and orphan indications

### Registration of clinical trials in pharmaceutical product development

### Overcoming market failures in medical product R&D

1. Diseases disproportionately affecting people in developing countries
2. Antimicrobials and antimicrobial resistance
3. The WHO R&D Blueprint for Action to Prevent Epidemics
4. WHO Expert Working Groups on R&D financing
5. Novel approaches to biomedical R&D
   - Monitoring health R&D
   - Grants
   - Prizes
   - Advance market commitments and advance purchase commitments
   - Priority review vouchers
   - Tax breaks for companies
   - Patent pools
   - Open source drug discovery and development
     - A global binding framework for R&D and a pooled fund for R&D
6. Product development partnerships
7. Research for neglected diseases: the role of pharmaceutical companies
8. WIPO Re:Search – Mobilizing intellectual property for global health

### Intellectual property rights in the innovation cycle

1. IP management within the broader legal and policy framework at national and international levels
2. Intellectual property and the product development process
3. Patent filing strategies in the public and private sectors and the exercise of patent rights
4. Pre-grant issues: questions of patentability
   - Patenting material that exists in nature
   - Incremental innovation and evergreening
     - Examples of incremental innovation
     - Evergreening
   - Medical indication claims
5. Post-grant issues: questions related to the use of patents
   - Research exception
   - Research tools
   - Licensing and assignment with respect to innovation
   - Patents in R&D agreements and other forms of collaboration
(e) Patent clusters and patent thickets

(f) Freedom-to-operate issues

(i) Defining freedom to operate

(ii) Freedom-to-operate strategies

E. Sharing of influenza viruses and access to vaccines and other benefits

1. WHO Global Influenza Surveillance and Response System

2. Intellectual property rights in the context of PIP negotiations

3. The PIP Framework

4. The PIP Framework and genetic sequence data

IV. Medical technologies: the access dimension

A. The context: health-systems-related determinants of access

1. Universal health coverage

2. International access frameworks: the value chain of medicines and health products

3. The meaning and measurement of “access”

   Affordability

   Availability

4. Generic medicines policies, price controls and reference pricing

   (a) Generic medicines policies

      (i) Supply-side measures

      (ii) Demand-side measures

      (iii) A comparison of selected generic medicines policies

   (b) Price control

   (c) Reference pricing

      (i) External reference pricing

      (ii) Internal reference pricing

   (d) Health technology assessments

   (e) Market entry agreements (MEAs)

      (i) Volume limitations

      (ii) Health-outcome-based agreements

   (f) Transparency across the value chain of medicines and health products

   (g) Differential pricing strategies

5. Taxes

6. Mark-ups

7. Rational selection and use of medicines

8. Effective and efficient procurement mechanisms

   (a) Principles for effective procurement

   (b) Tendering

   (c) Procurement and patent information
| (d) | Collective negotiation and pooled procurement | 207 |
| (e) | Reliable health and supply systems | 208 |

9. Sustainable financing 209

10. Manufacturing and technology transfer 209

11. Regulatory mechanisms and access to medical technologies 210
| (a) | WHO prequalification | 212 |
| (b) | Regulation of medical devices | 212 |
| (c) | Quality assurance by national medicines regulatory authorities | 213 |
| (d) | Regulatory cooperation and convergence: reducing barriers from technical regulations and assessment procedures | 213 |

(e) | Collaborative procedures for accelerated registration | 213 |

12. Substandard and falsified (SF) medical products 214
| (a) | Types of SF medical products | 214 |
| (b) | Counterfeit medical products and the TRIPS Agreement | 215 |
| (c) | The impact of SF medicines | 215 |
| (d) | How can SF medical products be combated? | 215 |

B. Access to health products in specific areas 217

1. HIV/AIDS 217
2. Antimicrobial resistance 219
3. Tuberculosis 220
4. Non-communicable diseases 221
5. Hepatitis C virus 224
6. Paediatric medicines 225
7. Vaccines 226
8. Medical devices 227

C. Intellectual-property-related determinants of access 229

1. Determinants of access prior to patent grant 230
| (a) | Diagnostic, surgical or therapeutic methods for the treatment of humans or animals | 230 |
| (b) | Patent examination and patent registration | 231 |
| (c) | Patent quality | 232 |

2. Pre-grant and post-grant review procedures 232
3. Post-grant determinants of access 233
| (a) | Exceptions and limitations to patent rights | 234 |
| (i) | Regulatory review (or “Bolar”) exception | 234 |
| (ii) | Compulsory licensing and government use | 235 |
| (iii) | The Special Compulsory Licensing System: an additional flexibility aimed at enhancing access to medicines | 241 |

(b) Voluntary licensing agreements 244
| (c) | Socially responsible licensing policies and management of IP developed at public institutions | 245 |
346

(d) March-in rights
246
(e) Open source licensing
246
(f) Exhaustion of rights and parallel imports
246
   (i) International exhaustion
247
   (ii) National exhaustion
247
   (iii) Regional exhaustion
247
   (iv) Policy options for exhaustion regimes
247
(g) Patent term extension and supplementary protection certificates
248
   (i) Statutory mechanisms to extend the term of a patent
248
   (ii) Supplementary protection certificates
249
(h) Enforcement of IP
250

4. Patent information and its relationship with public health policy
252

5. Review of relevant provisions in free trade agreements
252
   (a) Review of selected IP provisions
252
      (i) Patent law
258
      (ii) Patent term extension
258
      (iii) Grounds for granting compulsory licences
258
      (iv) Exhaustion regime
258
      (v) Regulatory exclusivities
258
      (vi) Patent linkage
259
      (vii) Enforcement
259
      (viii) Reaffirmation of TRIPS flexibilities and Doha Declaration principles
259
   (b) Investor–state dispute settlement
259
   (c) Major actors in FTAs
260
   (d) Economic impact analysis
260
   (e) The role of international organizations
261

D. Other trade-related determinants of access
262

1. International trade and tariff data of health products
262
   (a) International trade in health-related products
262
   (b) Tariff policy for health-related products
267

2. Competition law and policy
270
   (a) Application of competition law and policy to manufacturers of originator products
270
      (i) Strategic patenting
271
      (ii) Patent litigation
271
      (iii) Refusal to deal and restrictive licensing practices as abuse of dominance
272
      (iv) Interface of regulatory systems and competition law
274
   (b) Competition law and policy in relation to the generics sector
274
   (c) Application of competition policy to other actors in the health sector
276
   (d) The role of competition policy with regard to public procurement markets
277
<table>
<thead>
<tr>
<th>Annex I.</th>
<th>Resolutions of the UN General Assembly and UN Human Rights Council</th>
<th>Key Reports of the UN Special Rapporteur on the Right to Health</th>
<th>292</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Selected Resolutions of the United Nations General Assembly</td>
<td>294</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selected Resolutions of the United Nations Human Rights Council</td>
<td>295</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Key Reports of the United Nations Special Rapporteur on the Right to Health</td>
<td>296</td>
<td></td>
</tr>
<tr>
<td>Annex II.</td>
<td>Selected Resolutions and Decisions of the World Health Assembly</td>
<td>298</td>
<td></td>
</tr>
<tr>
<td>Annex III.</td>
<td>Special Compulsory Licences for Export of Medicines</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>A.</td>
<td>Operation of the System: context and scope</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>What is the System?</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>What products are covered by the System?</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>B.</td>
<td>Legal basis</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>C.</td>
<td>Use of the System</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Who can use the System as importers and exporters?</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>How can the System be used by WTO members?</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>(a)</td>
<td>How does an importing member use the System?</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>(i)</td>
<td>Notifying general intention to use the System</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>(ii)</td>
<td>Notifying the need to import specific pharmaceutical products</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>(b)</td>
<td>How does an exporting member use the System?</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Do regulatory authorities have to approve products manufactured under a special compulsory licence?</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Which safeguards against diversion need to be put in place?</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>How can the System be used at the regional level?</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>What does the WTO General Council Chairman’s statement add?</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>D.</td>
<td>Domestic implementation</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Importing members</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Exporting members</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Regional mechanism</td>
<td>308</td>
<td></td>
</tr>
</tbody>
</table>

Bibliography | 310
Abbreviations | 329
List of figures, tables and boxes | 334
Extended table of contents | 339